Regulatory & Legal

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.

South Korean tobacco giant KT&G just earned a flawless 'AAA' ESG rating, a first for its industry. What does this mean for investors and sustainability?

Tariff relief was a temporary fix. A powerful federal tax credit offers farmers a sustained way to fund the innovation they perform every day.

Ancient remedies meet modern AI. See how companies are using data and smart factories to transform traditional Chinese medicine into a global pharma force.

FC Supra du Québec isn't just building a team; it's building a brand. Their first signings reveal a bold, local-first strategy to win Quebec's heart.

With FDA approval and $80M in funding, ProVerum’s ProVee system aims to disrupt the BPH treatment market by prioritizing safety and patient quality of life.

After major setbacks, a surge of innovative drugs is set to transform the ALS market. We decode the science, the money, and what it means for patients.

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

Micro-cap BSEG racks up awards against giants like Variety, but with a volatile stock and weak fundamentals, can creative success spark a financial turnaround?

A new report shows slow progress on fixing ERs and long-term care, raising questions about government accountability and the real-world cost to Ontarians.

The eyewear giant is moving beyond frames, partnering to design custom chips. A strategic pivot to open-source hardware aims to redefine the market.

A landmark defense contract for 100,000 night-vision devices in Europe signals a major leap in military tech and raises the bar for NATO interoperability.

A new campaign tackles undiagnosed kidney disease. But is it just public health, or a savvy strategy to reshape a multi-billion dollar market?

Kim Thinggaard's return as CEO of Enemærke & Petersen signals a strategic doubling-down on the trust-based partnership model he pioneered.

A regulatory filing reveals a key investor's move as Alkermes' $2.1B bid for Avadel and its blockbuster narcolepsy drug, LUMRYZ, nears its final act.

As federal aid dwindles, a major health system invests in an innovative food network, betting on infrastructure to combat hunger and chronic disease.

A new partnership aims to rapidly upskill the U.S. public sector workforce, providing critical cyber defenses against a surge in AI-powered attacks.

As climate disasters escalate, a major insurer is shifting from payouts to prevention. We decode this signal and its implications for the future of risk.

A $2.4B deal for AI's future. A hedge fund's strategic play. We decode the battle for Alphawave, the company powering the next tech revolution.